An announcement from Sharps Technology, Inc. (STSS) is now available.
Sharps Technology, Inc. has secured a significant deal with Stericare Solutions, LLC, agreeing to supply 520 million units of their 10ml PP Sologard syringes over five years, with an expected revenue of over $50 million. The supply will commence with an initial delivery targeted for November 2024 and features an automatic renewal clause for additional one-year terms. The deal not only represents a lucrative arrangement but also fully commits the company’s EU manufacturing capacity for the product, highlighting Sharps Technology’s growing impact in the medical supply industry.
For detailed information about STSS stock, go to TipRanks’ Stock Analysis page.
